Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,091 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombus Clear all
Completed Phase 2 Interventional Results available

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440
View directory record Official record
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 8, 2026, 5:23 PM EDT
Completed No phase listed Observational

Prospective Investigation of Pulmonary Embolism Diagnosis III

NCT00241826
View directory record Official record
Conditions
Lung Diseases, Pulmonary Embolism
Interventions
Magnetic Resonance Angiography, Magnetic Resonance Venography
Procedure
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Atlanta, Georgia • Bethesda, Maryland • Rockville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 8, 2026, 5:23 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Reversing Ticagrelor's Effects With Fresh Platelets

NCT02201394
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor loading dose, Aspirin loading dose, Ticagrelor maintenance dose, Aspirin maintenance dose
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

NCT06062329
View directory record Official record
Conditions
Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Interventions
Symphony Thrombectomy System
Device
Lead sponsor
Imperative Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Not applicable Interventional

A Simple Clinical Tool to Help Diagnose Pulmonary Embolism: Phase 1

NCT01898637
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Augmented pulse oximetry using incentive spirometer., Incentive spirometer.
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 8, 2026, 5:23 PM EDT
Terminated Not applicable Interventional Results available

PICC Asymptomatic Thrombosis Study: A Pilot Study

NCT04920929
View directory record Official record
Conditions
Peripheral ICC
Interventions
Hydrophilic Biomaterial, Thermoplastic Polyurethane
Device
Lead sponsor
Access Vascular Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 8, 2026, 5:23 PM EDT
Completed No phase listed Observational

Microsurgical Breast Reconstruction & VTE

NCT03031457
View directory record Official record
Conditions
Breast Reconstruction, Venous Thromboembolism
Interventions
Duplex ultrasound
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 8, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

NCT00673439
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
fondaparinux, warfarin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

NCT04655586
View directory record Official record
Conditions
Covid19
Interventions
rNAPc2, Heparin
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 8, 2026, 5:23 PM EDT
Completed No phase listed Observational

Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge in Trauma

NCT03934983
View directory record Official record
Conditions
Blood Loss Massive, Trauma
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 8, 2026, 5:23 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

NCT02303431
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Edoxaban low dose, Edoxaban high dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
0 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439
View directory record Official record
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 8, 2026, 5:23 PM EDT
Withdrawn Phase 4 Interventional

Early Intrapleural TPA Instillation Versus Late

NCT03167281
View directory record Official record
Conditions
Tissue Plasminogen Activator
Interventions
early tPA and DNase
Combination Product
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 8, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, PEGPH20
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

NCT02205827
View directory record Official record
Conditions
Healthy
Interventions
Single-arm
Other
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 8, 2026, 5:23 PM EDT
Completed No phase listed Observational

New York City Mobile Interventional Stroke Team

NCT03048292
View directory record Official record
Conditions
Acute Stroke
Interventions
Acute Endovascular Stroke Treatment
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 8, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

NCT00499902
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy

NCT00389467
View directory record Official record
Conditions
Stroke
Interventions
Merci Retriever and Penumbra System
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 8, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

NCT04191928
View directory record Official record
Conditions
Pancreas Cancer, DVT, Pulmonary Embolism
Interventions
Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 8, 2026, 5:23 PM EDT